Characteristics of subjects
| Characteristic | BA | COPD | Control |
|---|---|---|---|
| N | 29 | 58 | 59 |
| Sex (M/F) | 6/23 | 54/4 | 23/36 |
| Age (years) | 66 (31–83) | 73 (56–83)*† | 66 (45–77) |
| Height (cm) | 155.5 (9.0) | 161.9 (7.0)† | 158.5 (9.8) |
| BSA (m2) | 1.54 (0.19) | 1.58 (0.14) | 1.57 (0.18) |
| Smoking history (pack-years) | 0 (0–3) | 57 (21–168)*† | 0 (0–5) |
| FVC (% predicted) | 86.1 (22.4) | 95.4 (16.8) | 99.1 (13.5) |
| FEV1 (L) | 1.54 (0.66)* | 1.39 (0.50)*† | 2.30 (0.63) |
| FEV1 (% predicted) | 76.5 (20.7)* | 53.2 (16.8)*† | 100.5 (16.1) |
| FEV1/FVC (%) | 68.2 (10.8)* | 44.2 (11.8)*† | 78.4 (5.0) |
| Use of inhaled corticosteroids (%) | 89.7 | 28.8 | 0 |
| Use of long-acting β agonists (%) | 48.3 | 23.7 | 0 |
| Use of long-acting muscarinic antagonist (%) | 0 | 30.5 | 0 |
| Use of oral corticosteroids (%) | 6.9 | 6.6 | 0 |
Values are mean (SD) or median (range).
*Significantly different from the control group.
†Significantly different from the BA group.
BA, bronchial asthma; BSA, body surface area.